First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

2024-511021-58-00 Protocol 20200469 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 2 Aug 2022 · Status Ongoing, recruitment ended · 6 EU/EEA countries · 15 sites · Protocol 20200469

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 184
Countries 6
Sites 15

Extensive Stage Small cell lung cancer (ES-SCLC)

Key facts

Sponsor
Amgen Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
2 Aug 2022 → ongoing
Decision date (initial)
2024-08-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-511021-58-00
EudraCT number
2021-005462-17
WHO UTN
U1111-1309-5174
ClinicalTrials.gov
NCT05361395

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Extensive Stage Small cell lung cancer (ES-SCLC)

VersionLevelCodeTermSystem organ class
21.1 PT 10041068 Small cell lung cancer extensive stage 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amgen Inc.

Sponsor organisation
Amgen Inc.
Address
1 Amgen Center Drive
City
Thousand Oaks
Postcode
91320-1730
Country
United States

Scientific contact point

Organisation
Amgen Inc.
Contact name
Medical Information

Public contact point

Organisation
Amgen Inc.
Contact name
Medical Information

Locations

6 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruitment ended 12 4
France Ongoing, recruitment ended 14 3
Germany Ongoing, recruitment ended 27 3
Italy Ongoing, recruitment ended 1 1
Netherlands Ongoing, recruitment ended 4 1
Spain Ongoing, recruitment ended 22 3
Rest of world
Australia, United States, Japan, Korea, Republic of, Switzerland, Israel, Taiwan, Canada
104

Investigational sites

Belgium

4 sites · Ongoing, recruitment ended
Antwerp University Hospital
Oncologie, Drie Eikenstraat 655, 2650, Edegem
Algemeen Ziekenhuis Delta
Pneumology, Deltalaan 1, 8800, Roeselare
Jessa Ziekenhuis
Respiratoire Oncologie, Stadsomvaart 11, 3500, Hasselt
Az Maria Middelares Gent
Pneumologie, Buitenring-Sint-Denijs 30, 9000, Gent

France

3 sites · Ongoing, recruitment ended
Institut Gustave Roussy
Departement d'Innovation Therapeutique et d'Essais Précoces, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Hospitalier Universitaire De Nantes
Service Pneumologie, Institut du thorax, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain
Centre Leon Berard
Service de Cancerologie Medicale, 28 Rue Laennec, 69008, Lyon

Germany

3 sites · Ongoing, recruitment ended
Technische Universitaet Dresden
Early Clinical Trial Unit - Universitaetskrebszentrum, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Medical Center - University Of Freiburg
Klinik für Tumorbiologie, Breisacher Str. 117, 79106, Freiburg
Universitaetsklinikum Essen AöR
Innere Klinik (Tumorforschung), Hufelandstrasse 55, Holsterhausen, Essen

Italy

1 site · Ongoing, recruitment ended
Fondazione IRCCS San Gerardo Dei Tintori
Unità Operativa Oncologia Medica, Via Giovanni Battista Pergolesi 33, 20900, Monza

Netherlands

1 site · Ongoing, recruitment ended
Universitair Medisch Centrum Groningen
Pulmonary medicine, Hanzeplein 1, 9713 GZ, Groningen

Spain

3 sites · Ongoing, recruitment ended
Hospital Germans Trias I Pujol
Servicio de Oncologia, Carretera Canyet 1a Planta, 08916, Badalona
Hospital Universitario 12 De Octubre
Servicio de Oncologia, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitari Vall D Hebron
Servicio de Oncologia, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2022-09-30 2023-02-21 2024-08-28
France 2022-08-25 2022-09-21 2024-08-28
Germany 2022-08-09 2022-08-25 2024-08-28
Italy 2023-01-27 2023-05-23 2024-08-28
Netherlands 2022-12-01 2023-07-13 2024-08-28
Spain 2022-08-02 2023-01-10 2024-08-28

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-05 Spain Acceptable with conditions
2024-08-23
2024-08-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-21 Spain Acceptable
2025-01-30
2025-01-31
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-19 Spain Acceptable
2025-05-22
2025-05-22
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-23 Acceptable
2025-05-22
2025-06-23
5 SUBSTANTIAL MODIFICATION SM-3 2025-07-04 Spain Acceptable
2025-10-09
2025-10-09
6 SUBSTANTIAL MODIFICATION SM-4 2025-11-28 Spain Acceptable
2026-02-09
2026-02-11